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Background: To select optimal candidates for limited lung resection, it is necessary to accurately differentiate the
non-invasive tumors from other small-sized lung cancer. Urinary N1, N12-diacetylspermine (DiAcSpm) has been reported
to be a useful tumor marker for various cancers. We aimed to examine the correlation between preoperative urinary
DiAcSpm levels and specific clinicopathological characteristics such as the histological tumor invasiveness in patients
with clinical stage IA non-small cell lung cancer (NSCLC).
Methods: We defined non-invasive tumors as NSCLC showing no vascular invasion, lymphatic permeation, pleural
invasion, or lymph node metastasis. Preoperative urine samples were obtained from 516 consecutive patients with
NSCLC resected at our institution between April 2008 and January 2013. Urinary DiAcSpm values were determined for
all preoperative urine samples using the colloid gold aggregation procedure. Among these patients, 171 patients with
clinical stage IA NSCLC met the criteria of our study cohort. Finally, we investigated the correlation between
non-invasive tumor and urinary DiAcSpm levels.
Results: The median urine DiAcSpm for males was 147.2 nmol/g creatinine and 161.8 nmol/g creatinine in females.
These median values were set as the cut-off values for each gender. Patients with higher urinary DiAcSpm levels
frequently had significantly elevated serum CEA (p = 0.023) and greater lymph node metastasis (p = 0.048),
lymphatic permeation (p = 0.046), and vascular invasion (p = 0.010). Compared with patients with non-invasive
tumors, patients with invasive tumors had a tumor size >2.0 cm (p = 0.001), serum CEA >5.0 mg/dL (p < 0.001),
high urinary DiAcSpm (p = 0.002), and a tumor disappearance rate (TDR) <0.75 (p < 0.001). Multivariate analysis
revealed that a tumor size < 2.0 cm (RR = 2.901, 95% CI; 1.372-6.136, p = 0.005), high urinary DiAcSpm (RR = 3.374, 95%
CI; 1.547-7.361, p = 0.002), and TDR < 0.75 (RR = 4.673, 95% CI; 2.178-10.027, p < 0.001) were independent predictors for
invasive tumors.
Conclusions: We successfully showed that there was a significant correlation between urinary DiAcSpm levels and
pathological tumor invasiveness in patients with clinical stage IA NSCLC. Further research would elucidate the clinical
usefulness of DiAcSpm levels as a predictor of tumor invasiveness.
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Surgery is one of the major therapeutic choices for pa-
tients with primary lung cancer. Specifically in clinical
stage IA non-small cell lung cancer (NSCLC), the stand-
ard treatment remains lobectomy and systematic hilar
and mediastinal lymph node dissection [1]. Recent ad-
vancements in diagnostic techniques have increased the
accuracy and frequency of detection of small-sized lung
tumors [2]. Using these advancements, a number of re-
searchers have attempted to prove the effectiveness of
limited lung resection; however, their studies have shown
a higher local recurrence rate after limited resection,
even though a negative surgical margin had been con-
firmed pathologically [3-5]. Possible explanations for
local recurrence following limited resection may include
insufficient surgical margins, misdiagnosis of nodal in-
volvement, or intrapulmonary lymphatic spread [6].
Limited resection is often performed in patients with
peripheral small-sized lung cancer, although two ran-
domized control trials comparing limited resection with
standard lobectomy in patients with clinical T1aN0M0
NSCLC are currently taking place in Japan. In order to
select optimal candidates for limited resection it is ne-
cessary to accurately differentiate between non-invasive
tumors that have been confirmed histologically and
other small-sized lung cancers. Several researchers aim-
ing to better characterize these tumors have reported
that a greater proportion of ground-glass opacity (GGO)
was a significant predictor of non-invasive lung cancer
[7,8]. Moreover, a recent report described that the pres-
ence of a micropapillary component was independently
associated with an increased risk of recurrence in patients
with stage I NSCLC treated with limited resection [9].
N1, N12-diacetylspermine (DiAcSpm) is a minor com-
ponent of urinary polyamines comprising less than 0.5%
of the total polyamines in healthy human urine [10]. It
has been widely accepted that actively proliferating cells
tend to excrete more polyamines as a result of the acti-
vation of intracellular polyamine metabolism and turn-
over. Furthermore, the presence of DiAcSpm is found to
be increased in advanced stage cancers [11]. In recent
years, we have reported that urinary DiAcSpm is often
significantly elevated in patients with various cancers, in-
cluding early stage disease [11]. Based on this finding,
we aimed to examine the correlation between preopera-
tive urinary DiAcSpm levels and clinicopathological
characteristics such as the histological invasiveness of tu-
mors in patients with clinical stage IA NSCLC.
Methods
Urine samples were obtained before treatment from 516
consecutive patients who were diagnosed with operable
NSCLC at Tokyo Metropolitan Cancer and Infectious
Disease Center Komagome Hospital between April 2008and January 2013. Among these patients, 171 consecu-
tive patients with clinical stage IA NSCLC were consist-
ent with our study cohort. We received prior approval to
use patient urine samples from the ethical committees at
Tokyo Metropolitan Cancer and Infectious Disease Cen-
ter Komagome Hospital and Tokyo Metropolitan Insti-
tute of Medical Science. Informed consent was obtained
from all patients and approved by the Institution Review
Board.Determination of urinary DiAcSpm using the colloid gold
aggregation procedure
Urine samples were supplemented with 3 mmol/L NaN3
and stored at −20°C, as previously described [12]. Urin-
ary DiAcSpm was measured by the colloidal gold aggre-
gation procedure using a JCM BM-6010 automatic
biochemical analyzer (JEOL, Tokyo, Japan). The colloidal
gold aggregation procedure relies on the binding specifi-
city of bovine serum albumin (BSA)-acetylspermine
conjugate, a DiAcSpm mimic, to colloidal gold-antibody
complexes resulting in a stable red-purple solution.
Addition of the BSA-acetylspermine conjugate into the so-
lution induces a color change from red-purple to grey due
to aggregation of the colloidal gold particles. DiAcSpm, a
monovalent antigen that cannot cross-link multiple gold
particles, competes with the BSA-acetylspermine conju-
gate for binding to the colloidal gold-antibody complexes.
Therefore, when a urinary sample containing DiAcSpm is
added to the colloidal system, DiAcSpm competitively
binds to the colloidal gold-antibody complexes and sup-
presses color change. Thus, by using this competitive col-
loidal system, the concentration of DiAcSpm in a urine
sample can be determined by measuring the color change
of the solution. Auto DiAcSpm® (Alfresa Pharma Co.,
Osaka, Japan), a reagent that can be used in automated
clinical analyzers, is commercially available. The concen-
tration of DiAcSpm determined by the colloidal gold
aggregation procedure have been shown to closely corres-
pond with those determined by mass spectrometric
analysis [13]. Urine creatinine levels were measured en-
zymatically using the NESCAUTO® VLII CRE reagent
(Alfresa Pharma Co., Osaka, Japan) on a JCM BM-6010
automated biochemical analyzer (JEOL, Tokyo, Japan).Clinicopathological assessment
All clinicopathological data were retrieved from patient
medical records. Preoperative evaluation included a
physical examination, blood chemistry analysis, meas-
urement of tumor markers, bronchoscopy, chest radiog-
raphy, computed tomography (CT), brain MRI, and
bone scintigraphy. Integrated positron emission tomog-
raphy scan and CT scan (PET/CT) were also performed
where appropriate. Clinical lymph node metastasis was
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the short axis by CT scan and/or hypermetabolic lymph
nodes on PET/CT scans. Histological confirmation of
lymph node metastasis was made using endobronchial
ultrasound-guided transbronchial needle aspiration of
enlarged lymph nodes. All patients underwent a lobec-
tomy or bilobectomy and systematic lymph node dissec-
tion for resection of the primary lesion.
All surgical specimens underwent thorough patho-
logical examination. Each tumor was diagnosed accord-
ing to the current histological classification of the World
Health Organization [14] and was staged according to
the tumor node metastasis classification of the Inter-
national Union against Cancer, 7th edition [15]. Vascular
and pleural invasion and lymphatic permeation were
evaluated using both hematoxylin and eosin (HE) section
staining and Victoria Blue van Gieson (VvG) section
staining.
Non-invasive tumor was defined as NSCLC showing
no vascular invasion, pleural invasion, lymphatic per-
meation, or lymph node metastasis. The following clini-
copathologic information was collected from patient
medical records: age (categorized into two groups,
≤69 years and >69 years, according to the median age),
gender, tumor size, preoperative serum CEA level (di-
chotomized at the normal upper limit of 5 mg/dL),
pathological lymph node involvement, vascular invasion,
pleural invasion, lymphatic permeation, histological type,
and pathological stage.
Of the 171 NSCLC lesions, 140 adenocarcinomas were
identified and classified according to the adenocarcin-
oma classification newly proposed by the International
Association for the Study of Lung Cancer, American
Thoracic Society, and the European Respiratory Society
(IASLC/ATS/ERS) [16]. The adenocarcinomas were di-
vided into three groups: (1) adenocarcinoma in situ
(AIS), (2) minimally invasive adenocarcinoma (MIA),
and (3) invasive adenocarcinoma (I-ADC). Then, we
evaluated the correlation between histological invasive-
ness of the tumors, defined according to the above clas-
sification, and the specific clinicopathological factors
described above.
Measurement of tumor disappearance rate on chest CT
We calculated a tumor disappearance rate (TDR) using
the following tumor dimension measurements on high-
resolution chest CTs [17]: pDmax, which is the maximum
dimension of a tumor on pulmonary window setting
images; pDperp, the largest dimension perpendicular to
the maximum axis on pulmonary window setting im-
ages; mDmax, the maximum dimension of a tumor on
mediastinal window setting images; and mDperp, the
largest dimension perpendicular to the maximum axis
on mediastinal window setting images. Using thesemeasurements, the TDR was then calculated using the
following formula:
TDR ¼ 1 – mDmax  mDperpð Þ = pDmax  pDperpð Þ
The TDR threshold was set at 0.75, as previously de-
scribed [18].
Statistical analysis
Two-category comparisons were performed using the
Pearson Chi-Square (χ2) Test and the Fisher’s Exact Test
for categorical variables, and the Mann–Whitney U Test
was performed for continuous variables. All statistical
tests were two-sided, and p < 0.05 were considered sta-
tistically significant. To determine the impact of factors
considered significant predictors of survival by earlier
univariate analysis, a multivariate analysis was performed
on these predictors using a logistic regression model. All
statistical analyses were performed using SPSS software
(version 20; SPSS Inc., Chicago, III).
Results
Patient characteristics
Our cohort consisted of 84 males and 87 females. Ages
ranged from 36 to 89 years, with a median age of
69 years. Tumor size from the resected specimens
ranged from 0.8 to 3.5 cm, with a median of 1.8 cm.
Within the study cohort, there were 137 adenocarcin-
omas, 24 squamous cell carcinomas, and 10 with other
histology (2 adenosquamous carcinomas, 2 large cell car-
cinomas, 2 non-small cell carcinomas, 2 large cell neuro-
endocrine carcinomas, 1 clear cell carcinoma, and 1
carcinoid). There were 136 identified as pathological
stage IA tumors, 121 as stage IB, 7 as stage IIA, and 7 as
stage IIIA. Tumor stage was increased in 35 patients due
to additional diagnoses following surgery. Discoveries
that contributed to the up-staging included lymph node
metastasis in 15 patients, an actual tumor size > 3 cm in
8 patients, and pleural invasion in 26 patients. Further,
lymphatic permeation was seen in 24 patients and vascu-
lar invasion in 39 patients. A summary of patients and
their pathological characteristics is presented in Table 1.
The median urine DiAcSpm was 147.2 nmol/g creatinine
(range: 3.7-3918.8) in males and 161.8 nmol/g creatinine
(range: 66.0-867.6) in females. These median values were
set as the cut-off values for urine DiAcSpm for each
gender, as previous reports have demonstrated that the
urine DiAcSpm values for healthy women are higher
than those for men [12].
Measurement of tumor disappearance rate on chest
computed tomography
When we applied 0.75 as the cut-off value for TDR where
TDR was used to test the correlation with pathological
Table 1 Baseline characteristics of initial study cohort
(n = 171)
Age












squamous cell carcinoma 24
large cell carcinoma 2
large cell neuroendocrine carcinoma 2
adenosquamous carcinoma 2
carcinoid 1

















Table 2 Correlation between urine DiAcSpm and
clinicopathological factors






>69 38 46 0.286
Smoking history
Never-smoker 32 26
Smoker 53 60 0.335
Tumor size (cm)
≤2.0 55 49
>2.0 30 37 0.348
Serum CEA level (mg/dL)
≤5.0 79 69
>5.0 6 17 0.023
TDR
≥0.75 25 24
<0.75 60 62 0.867
Histological type
adenocarcinoma 68 69
non-adenocarcinoma 17 17 0.970
Lymph node metastasis
N0 82 75
N1-2 3 11 0.048
Lymphatic permeation
negative 78 69
positive 7 17 0.046
Vascular invasion
negative 73 59
positive 12 27 0.010
Pleural invasion
pl0 75 70
pl1-2 10 16 0.287
*Fisher’s exact test, DiAcSpm = diacetylspermine, CEA = carcinoembryonic
antigen level.
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values of 59.2% and 74.6%, respectively, with the best
predictive accuracy of 70.2%. For urinary DiAcSpm, we
applied cut-off values of 147.2 for males and 161.8 for
females and achieved 69.4% sensitivity and 57.4% speci-
ficity which yielded a prediction accuracy of 60.8% for
pathological invasiveness. When the TDR and urinary
DiAcSPM were inversely combined, the predictive value
of non-invasive tumor was 94.9% (37 of 39).Correlation between clinicopathological characteristics
and urinary DiAcSpm
We evaluated the data to determine whether there was
a correlation between urinary DiAcSpm and clinico-
pathological characteristics (Table 2). The high urinary
DiAcSpm group often showed significantly elevated
serum CEA (p = 0.023), lymph node metastasis (p =
0.048), lymphatic permeation (p = 0.046), and vascular
invasion (p = 0.010) compared with the low urinary
DiAcSpm group.









>69 30 54 0.062
Gender
male 30 54
female 19 68 0.062
Smoking history
Never-smoker 11 47
Smoker 38 75 0.051
Tumor size (cm)
≤2.0 20 84
>2.0 29 38 0.001
Serum CEA level (mg/dL)
≤5.0 35 113
>5.0 14 9 <0.001
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differences between the absolute values of urinary
DiAcSpm and serum CEA level (≤5.0 mg/dL vs. >5.0 mg/
dL), lymph node metastasis (N0 vs. N1-2), vascular in-
vasion (positive vs. negative), lymphatic permeation
(positive vs. negative), histological type (adenocarcin-
oma vs. others), tumor size (≤2.0 cm vs. >2.0 cm), and
TDR (≥0.75 vs. <0.75). The results of these tests are
presented in Table 2 and are as follows: The urinary
DiAcSpm from the normal serum CEA group and N0
group was significantly lower than the elevated serum
CEA group (p = 0.044) and N1-2 group (p = 0.014), re-
spectively. Urinary DiAcSpm from the negative vascular
invasion group was significantly lower than the positive
vascular invasion group (p = 0.002). Urinary DiAcSpm
from the negative lymphatic permeation group was sig-
nificantly lower than the positive lymphatic permeation
group (p = 0.038). In contrast, there were no significant
differences in urinary DiAcSpm in groups with adeno-
carcinoma (p = 0.585), tumor size ≤2.0 cm and >2.0 cm
(p = 0.249) or TDR (≥0.75 and <0.75 (p = 0.489).Histological type
adenocarcinoma 35 102




high 34 520 0.002
TDR
≥0.75 4 45
<0.75 45 77 <0.001
*Fisher’s exact test, DiAcSpm = diacetylspermine, CEA = carcinoembryonic
antigen level, TDR = tumor disappearance rate.Correlation between pathologically confirmed tumor
invasiveness and clinicopathological factors
We investigated the relationship between pathologically
confirmed tumor invasiveness and clinicopathological
factors (Table 3). There were 122 cases of non-invasive
tumors and 49 cases of invasive tumors. Tumor size
>2.0 cm (p = 0.001), serum CEA >5.0 mg/dL (p < 0.001),
high urinary DiAcSpm (p = 0.002), and TDR > 0.75 (p <
0.001) were more frequently observed in patients with
invasive tumors than in those with non-invasive tumors.
Pathologically confirmed tumor invasiveness was not
significantly affected by age, gender, smoking history, or
histological type.
Multivariate analysis
We performed a multivariate analysis to determine in-
dependent predictors of pathologically confirmed inva-
sive tumors (Table 4). A tumor size >2.0 cm (Risk ratio
(RR) = 2.871, 95% confidence interval (CI): 1.347-6.119,
p = 0.006), high urinary DiAcSpm (RR = 3.374, 95% CI;
1.547-7.361, p = 0.002), and TDR < 0.75 (RR = 6.103, 95%
CI; 1.962-18.981, p < 0.001) were independent predictors
of invasive tumors. However, serum CEA was not an inde-
pendent predictor of pathologically confirmed tumor inva-
sive tumors.
Correlation between histological invasiveness defined in
IASLC/ATS/ERS classification and clinicopathological
characteristics
Of 171 NSCLC lesions, 140 stage IA adenocarcinomas
were separately analyzed to determine the correlationbetween histological invasiveness, as defined by IASLC/
ATS/ERS classification, and clinicopathological factors.
We confirmed 87 cases of non-invasive adenocarcinomas
and 53 cases of invasive adenocarcinomas. Male gender
(p = 0.010), smoker (p = 0.033), tumor size >2.0 cm (p <
0.001), serum CEA >5.0 mg/dL (p = 0.006), high urinary
DiAcSpm (p < 0.001), and TDR > 0.75 (p = 0.023) were
more frequently associated with patients with invasive
tumors than in patients with non-invasive tumors
(Additional file 1: Table S1). Further, a tumor size >2.0 cm
(RR = 3.249, 95% CI; 1.380-7.650, p = 0.007), high urinary
DiAcSpm (RR = 8.208, 95% CI; 3.470-19.417, p < 0.001),
and TDR < 0.75 (RR = 2.783, 95% CI; 1.090-7.108, p =
0.032) were independent predictors of invasive tumors
(Additional file 1: Table S2). However, gender, smoking
history, and serum CEA were not found to be significant
independent predictors of histological invasiveness in clin-
ical stage IA adenocarcinomas.
Table 4 Multivariate analysis for prediction of non-invasive NSCLC among clinical stage IA patients
Variables Risk factors Risk ratio for invasive tumor 95% CI p-value*
Tumor size (cm) >2.0 2.871 1.347-6.119 0.006
Urine DiAcSpm level (nmol/g creatinine) high 3.374 2.736-7.361 0.002
Serum CEA (mg/dL) ≥5.0 2.316 0.841-6.377 0.104
TDR < 0.75 6.103 1.962-18.98 <0.001
*Logistic regression analysis, CI = confidence interval, DiAcSpm = diacetylspermine, CEA = serum carcinoembryonic antigen level, TDR = tumor disappearance rate.
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The extent of pulmonary resections for small-sized
NSCLC remains a considerable concern for thoracic sur-
geons. The major challenge is determining which sub-
groups of NSCLCs are suitable candidates for limited
resection. Several investigators have reported that patho-
logically confirmed invasive factors was not a rare occur-
rence and tumors showed a considerable recurrence
rate, even when a patient’s tumor was classified as clinical
stage IA NSCLC [1,19]. Currently, there are randomized
controlled trials underway to compare the differences in
outcome between a lobectomy and a limited resection in
patients with clinical stage IA NSCLC.
Previous reports have shown that pathologically con-
firmed invasive factors from resected NSCLCs were
strongly correlated with more frequent nodal involve-
ment and poorer outcomes [19,20]. Based on these find-
ings, it is widely accepted that the ability to predict
pathologically non-invasiveness is essential for identify-
ing optimal candidates for limited resection. A number
of retrospective studies have indicated that tumor non-
invasiveness was frequently confirmed in resected lung
cancers smaller than 2 cm [8,20]. However, there are re-
ports indicating the occurrence of lymph node metasta-
sis in 6% to 12% of small-sized NSCLC [19]. In the
current study, positive lymph node metastasis was ob-
served in 14 of 171 (8.2%) patients, which is consistent
with previous reports. According to these results, it is
suggested that tumor size alone cannot predict the
pathologic invasiveness of NSCLC.
Several reports have demonstrated that the TDR on
High-Resolution Computed Tomography (HRCT) was a
significant predictor of pathologically confirmed inva-
siveness in small-sized NSCLC [8,19]. Alternatively, it
has been reported that the percentage of solid opacity of
a tumor on HRCT is a useful predictor of a non-invasive
tumor [20-22]. These reports also demonstrated that the
TDR alone is insufficient to perfectly predict non-
invasive tumors.
In this study we have successfully demonstrated that
urinary DiAcSpm is a useful marker that significantly
correlates with pathologically confirmed non-invasive tu-
mors; thus, it may be used to identify suitable candidates
for limited resection. DiAcSpm is one of the minor poly-
amine components secreted in human urine. Polyamineexcretion increases with tumor cell proliferation via the
activation of intracellular polyamine metabolism and
turnover [23]. Chen and colleagues demonstrated that
an increase in DiAcSpm levels is associated with the
stimulation of oxidative catabolism of polyamines [24].
Moreover, Kuwata et al. recently reported that DiAcSpm
levels were elevated in tumor tissues from both primary
sites and liver metastasis, suggesting that DiAcSpm may
be produced from cancer cells themselves [25].
We have previously reported that DiAcSpm is fre-
quently elevated in patients with various cancers, includ-
ing colorectal, breast, lung, prostate, testicular, renal,
and pelvic cancer, with very low false-negative incidence
[11,26]. It should be noted that compared to conven-
tional tumor markers like CEA and CA19-9, urinary
DiAcSpm level is more frequently elevated in the earlier
stages of colorectal and breast cancer. In addition, it has
been reported that poor prognosis of patients with uro-
genital malignancies is associated with an increase in
urinary DiAcSpm [27]. Hiramatsu et al. also reported
that there was a strong positive correlation between
urinary DiAcSpm and disease progression [27], which is
consistent with the current study results that high urin-
ary DiAcSpm is positively correlated with tumor inva-
siveness (i.e., lymphatic permeation, vascular invasion,
and lymph node metastasis). Therefore, we believe the
results of the current study clearly indicate that urinary
DiAcSpm level is significantly associated with patho-
logically confirmed tumor invasiveness in stage IA
NSCLC.
The value for urinary DiAcSpm is usually normalized
to creatinine (nmol DiAcSpm/g creatinine). Because
DiAcSpm is not reabsorbed by the renal brush border,
the glomerular clearance of DiAcSpm is comparable
to that of creatinine [28]. This helps to explain why
DiAcSpm, which is produced in tissues of early stage
cancers and subsequently excreted into circulation, is re-
covered in the urine without significant loss and, there-
fore, may serve as a useful tumor marker that is highly
sensitive for early stage cancers [11]. In one of our previ-
ous studies, we reported that the value for urinary
DiAcSpm in a healthy male significantly differed from
that in a healthy female [12]. We therefore separately
employed the cut-off values for urinary DiAcSpm by
gender.
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DiAcSpm due to its high specificity for predicting non-
invasive tumors. TDR was confirmed to be independ-
ently correlated with pathological tumor invasiveness.
Thus, we have shown that the combination of TDR and
urinary DiAcSpm was strongly correlated with patho-
logical invasiveness. Our further analysis evaluating the
correlation between clinicopathological characteristics
and histological invasiveness, as defined in the IASLC/
ATS/ERS classification of adenocarcinomas (Additional
file 1: Tables S1 and S2), strongly supported the results
from the analysis of the original patient cohort (Tables 2,
3, 4). In fact, the latter analysis revealed a stronger cor-
relation between histological invasiveness and urinary
DiAcSpm.
The mechanisms underlying an increase in urinary
DiAcSpm value in cancer patients have not been fully
understood, although a considerable amount of literature
has reported the usefulness of urinary DiAcSpm as a
novel tumor marker. The current study and further in-
vestigation may contribute in clarifying the mechanism
and clinical significance of DiAcSpm.
There are several limitations that may exist in the
current study. First, the study involved retrospective data
collection in a small cohort of patients, and there is a
possibility for bias due to selecting clinical stage IA. Fur-
ther, although the HRCTs were retrospectively reviewed
by two experienced observers who were blind to patient
identification, image evaluation by the observers is sub-
jective, thus, our evaluations may lack reproducibility.
Secondly, we could not definitively confirm the appro-
priate use of limited resection, because our data did not
include survival data. Therefore, in a future study, we
should perform a follow-up with patients in the current
cohort.
Conclusion
In conclusion, our data show that there is a significant
correlation between urinary DiAcSpm and pathological
tumor invasiveness in patients with clinical stage IA
NSCLC. Future investigations should aim to elucidate
the oncological significance and clinical usefulness of
DiAcSpm.
Additional file
Additional file 1: Table S1. Relationship between histological
invasiveness in IASLC/ATS/ERS classification and clinicopathological
factors in adenocarcinoma cases. Table S2. Multivariate analysis for
prediction of invasive adenocarcinoma among clinical Stage IA patients.
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